Mucosal vaccination with recombinantly attenuated staphylococcal enterotoxin B and protection in a murine model

Infection and Immunity

Volumn 69, Issue 4, 2001, Pages 2031-2036

  Stiles, B G ^a   Garza, A R ^a   Ulrich, R G ^a   Boles, J W ^a  

^a UNITED STATES ARMY MEDICAL RESEARCH INSTITUTE OF INFECTIOUS DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLERA TOXIN; IMMUNOGLOBULIN; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; IMMUNOLOGICAL ADJUVANT; STAPHYLOCOCCUS ENTEROTOXIN B;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY PRODUCTION; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; IMMUNIZATION; IMMUNOGLOBULIN BLOOD LEVEL; IMMUNOGLOBULIN PRODUCTION; LD 50; MOUSE; NONHUMAN; PRIORITY JOURNAL; SEPTIC SHOCK; VACCINATION;

ADMINISTRATION, INTRANASAL; ADMINISTRATION, ORAL; ANIMALS; ANTIBODIES, BACTERIAL; BACTERIAL VACCINES; CHOLERA TOXIN; ENTEROTOXINS; IMMUNITY, MUCOSAL; MICE; MICE, INBRED BALB C; SHOCK, SEPTIC; STAPHYLOCOCCUS AUREUS; VACCINATION; VACCINES, SYNTHETIC;

EID: 0035081046     PISSN: 00199567     EISSN: None     Source Type: Journal    
DOI: 10.1128/IAI.69.4.2031-2036.2001     Document Type: Article

References (31)

1. Relationship between enterotoxic- and T lymphocyte-stimulating activity of staphylococcal enterotoxin B
2. Recombinant Norwalk virus-like particles given orally to volunteers: Phase I study
3. Oral immunization with recombinant Norwalk virus-like particles induces a systemic and mucosal immune response in mice
4. Superantigen vaccines: A comparative study of genetically attenuated receptor-binding mutants of staphylococcal enterotoxin A
5. Immunization of rhesus monkeys with enterotoxoid B
6. The role of cAMP in mucosal adjuvanticity of Escherichia coli heat-labile enterotoxin (LT)
7. Mucosal and systemic immunogenicity of a recombinant, non-ADP-ribosylating pertussis toxin: Effects of formaldehyde treatment
8. Exotoxins of Staphylococcus aureus
9. Formaldehyde treatment of proteins can constrain presentation to T cells by limiting antigen processing
10. Cholera toxin as a mucosal adjuvant
11. Superantigens produced by infectious pathogens: Molecular mechanism of action and biological significance
12. Predominant Staphylococcus aureus isolated from antibiotic-associated diarrhea is clinically relevant and produces enterotoxin A and the bicomponent toxin LukE-LukD
13. Reduced susceptibility of Staphylococcus aureus to vancomycin-Japan, 1996
14. Potentiation of inhaled staphylococcal enterotoxin B-induced toxicity by lipopolysaccharide in mice
15. Immunogenicity and efficacy against lethal aerosol staphylococcal enterotoxin B challenge in monkeys by intramuscular and respiratory delivery of proteosome-toxoid vaccines
16. Intranasal and intramuscular proteosome-staphylococcal enterotoxin B (SEB) toxoid vaccines: Immunogenicity and efficacy against lethal SEB intoxication in mice
17. Toxic shock syndrome. A newly recognized complication of influenza and influenza-like illness
18. Induction of clonal anergy by oral administration of staphylococcal enterotoxin B
19. Protection against Staphylococcus aureus sepsis by vaccination with recombinant staphylococcal enterotoxin A devoid of superantigenicity
20. Rotavirus virus-like particles administered mucosally induce protective immunity
21. Oral administration of the bacterial superantigen staphylococcal enterotoxin B induces activation and cytokine production by T cells in murine gut-associated lymphoid tissue
22. Inactivation of staphylococcal enterotoxin A by chemical modification
23. Toxicity of staphylococcal enterotoxin potentiated by lipopolysaccharide: Major histocompatibility complex class II molecule dependency and cytokine release
24. Biological activity of toxic shock syndrome toxin 1 and a site-directed mutant, H135A, in a lipopolysaccharide-potentiated mouse lethality model
25. Early development of a temporary resistance to the emetic action of staphylococcal enterotoxin
26. Humoral immunity to aerosolized staphylococcal enterotoxin B (SEB), a superantigen, in monkeys vaccinated with SEB toxoid-containing microspheres
27. Evolving superantigens of Staphylococcus aureus
28. Development of engineered vaccines effective against structurally related bacterial superantigens
29. Staphylococcal enterotoxin B mutants (N23K and F44S): Biological effects and vaccine potential in a mouse model
30. Differential immune responses to staphylococcal enterotoxin B mutations in a hydrophobic loop dominating the interface with major histocompatibility complex class II receptors
31. Mutants in the ADP-ribosyltransferase cleft of cholera toxin lack diarrheagenicity but retain adjuvanticity